RxDoctor Payments Data

Rahman Shah, MD

Interventional Cardiology · Panama City, FLNPI 1780632380

Payments from drug & device makers

$1,980in general payments, 2019–2025

Across 99 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$319
  • AstraZeneca$233
  • Novartis$220
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$204
  • Amgen$201
  • Actelion Pharmaceuticals US, Inc.$194
  • plus $608 from 12 others

What the payments were for

  • Food & beverage$1,89196%
  • Education$894%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,980 in reported general payments places this provider in the 15th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$87,254
Medicare patients
564
Services billed
1,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$84,012
EntrestoSacubitril/Valsartan60$69,498
XareltoRivaroxaban21$28,055
BrilintaTicagrelor28$24,151
FarxigaDapagliflozin Propanediol13$22,275
Metoprolol Succinate233$3,650
Ranolazine ErRanolazine11$1,378
Atorvastatin Calcium213$1,373
Carvedilol190$1,356
Amlodipine Besylate227$1,007
ClopidogrelClopidogrel Bisulfate100$909
Ezetimibe64$790
Spironolactone87$702
Prasugrel Hcl26$612
Lisinopril107$532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$84,01298 claims
NovartisEntresto$220$69,49860 claims
AstraZenecaBrilinta, Farxiga$233$46,42541 claims
Johnson & JohnsonXarelto$129$28,05521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →